New Zealand markets close in 3 hours 26 minutes
  • NZX 50

    11,012.77
    -187.27 (-1.67%)
     
  • NZD/USD

    0.5731
    +0.0001 (+0.01%)
     
  • NZD/EUR

    0.5833
    +0.0000 (+0.01%)
     
  • ALL ORDS

    6,720.60
    -40.00 (-0.59%)
     
  • ASX 200

    6,522.30
    -32.70 (-0.50%)
     
  • OIL

    81.35
    +0.12 (+0.15%)
     
  • GOLD

    1,671.60
    +3.00 (+0.18%)
     
  • NASDAQ

    11,164.78
    -329.05 (-2.86%)
     
  • FTSE

    6,881.59
    -123.80 (-1.77%)
     
  • Dow Jones

    29,225.61
    -458.13 (-1.54%)
     
  • DAX

    11,975.55
    -207.73 (-1.71%)
     
  • Hang Seng

    17,165.87
    -85.01 (-0.49%)
     
  • NIKKEI 225

    26,158.18
    -263.87 (-1.00%)
     
  • NZD/JPY

    82.8110
    +0.0640 (+0.08%)
     

What You Need To Know About vTv Therapeutics Inc.'s (NASDAQ:VTVT) Investor Composition

·4-min read

A look at the shareholders of vTv Therapeutics Inc. (NASDAQ:VTVT) can tell us which group is most powerful. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. We also tend to see lower insider ownership in companies that were previously publicly owned.

vTv Therapeutics is a smaller company with a market capitalization of US$134m, so it may still be flying under the radar of many institutional investors. Our analysis of the ownership of the company, below, shows that institutions are noticeable on the share registry. Let's delve deeper into each type of owner, to discover more about vTv Therapeutics.

See our latest analysis for vTv Therapeutics

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About vTv Therapeutics?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

As you can see, institutional investors have a fair amount of stake in vTv Therapeutics. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at vTv Therapeutics' earnings history below. Of course, the future is what really matters.

earnings-and-revenue-growth
earnings-and-revenue-growth

vTv Therapeutics is not owned by hedge funds. The company's largest shareholder is MacAndrews & Forbes Incorporated, with ownership of 45%. With 13% and 3.6% of the shares outstanding respectively, Group 42 Holding Ltd and Ronald Perelman are the second and third largest shareholders.

A more detailed study of the shareholder registry showed us that 2 of the top shareholders have a considerable amount of ownership in the company, via their 58% stake.

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There is a little analyst coverage of the stock, but not much. So there is room for it to gain more coverage.

Insider Ownership Of vTv Therapeutics

The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

We can report that insiders do own shares in vTv Therapeutics Inc.. As individuals, the insiders collectively own US$5.0m worth of the US$134m company. Some would say this shows alignment of interests between shareholders and the board, though we generally prefer to see bigger insider holdings. But it might be worth checking if those insiders have been selling.

General Public Ownership

The general public, who are usually individual investors, hold a 32% stake in vTv Therapeutics. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.

Private Equity Ownership

With a stake of 45%, private equity firms could influence the vTv Therapeutics board. Some investors might be encouraged by this, since private equity are sometimes able to encourage strategies that help the market see the value in the company. Alternatively, those holders might be exiting the investment after taking it public.

Private Company Ownership

It seems that Private Companies own 13%, of the vTv Therapeutics stock. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.

Next Steps:

It's always worth thinking about the different groups who own shares in a company. But to understand vTv Therapeutics better, we need to consider many other factors. For instance, we've identified 4 warning signs for vTv Therapeutics (1 is concerning) that you should be aware of.

If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here